(Q35945719)

11 August 2017

1 reference

title

The role of existing and newer calcium channel blockers in the treatment of hypertension (English)

1 reference

11 August 2017

1 reference

Jan Basile

1

1 reference

11 August 2017

language of work or name

1 reference

1 November 2004

1 reference

Journal of Clinical Hypertension

11 August 2017

published in

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

621-29; quiz 630-1

1 reference

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Do calcium channel blockers increase the risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Lercanidipine : a review of its efficacy in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Lacidipine: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Treatment of isolated systolic hypertension: the SHELL study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2004.03683.X

10.1111/J.1524-6175.2004.03683.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference